Skip to content

Study · Randomized controlled trial · n = 60 · 2014

15 results

Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes.

Shao N, Kuang HY, Hao M, Gao XY, Lin WJ, Zou W

Diabetes/metabolism research and reviews1 Sept 2014Cited by 158 (Europe PMC)

PMID24823873 (opens in a new tab)DOI10.1002/dmrr.2561 (opens in a new tab)PepBankPUB-24823873
Publisher pagePubMedAsk about this study
Jump to 15 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study15

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In patients with obesity, fatty liver and diabetes, exenatide (with background insulin glargine) decreased body weight whereas intensive insulin aspart plus glargine increased it.

    In plain wordsIn people with obesity, fatty liver and diabetes, weight fell with exenatide but rose with intensive insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 60

    Comparator
    Insulin aspart plus insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Body weight and waist circumference were significantly decreased in the exenatide group but increased in the intensive insulin group (p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In patients with obesity, fatty liver and diabetes, exenatide (with background insulin glargine) decreased waist circumference whereas intensive insulin aspart plus glargine increased it.

    In plain wordsIn people with obesity, fatty liver and diabetes, waist size fell with exenatide but rose with intensive insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseWaist circumference
    Study

    n = 60

    Comparator
    Insulin aspart plus insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Body weight and waist circumference were significantly decreased in the exenatide group but increased in the intensive insulin group (p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In patients with obesity, fatty liver and diabetes, ALT was significantly lower with exenatide (with background insulin glargine) than with intensive insulin aspart plus glargine.

    In plain wordsIn people with obesity, fatty liver and diabetes, ALT was lower with exenatide than with intensive insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseALT
    Study

    n = 60

    Comparator
    Insulin aspart plus insulin glargine
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyl transpeptidase (γGGT) in the exenatide group were significantly lower than in the intensive insulin group (p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In patients with obesity, fatty liver and diabetes, AST was significantly lower with exenatide (with background insulin glargine) than with intensive insulin aspart plus glargine.

    In plain wordsIn people with obesity, fatty liver and diabetes, AST was lower with exenatide than with intensive insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAST
    Study

    n = 60

    Comparator
    Insulin aspart plus insulin glargine
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyl transpeptidase (γGGT) in the exenatide group were significantly lower than in the intensive insulin group (p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In patients with obesity, fatty liver and diabetes, γGGT was significantly lower with exenatide (with background insulin glargine) than with intensive insulin aspart plus glargine.

    In plain wordsIn people with obesity, fatty liver and diabetes, γGGT was lower with exenatide than with intensive insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseγGGT
    Study

    n = 60

    Comparator
    Insulin aspart plus insulin glargine
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and γ-glutamyl transpeptidase (γGGT) in the exenatide group were significantly lower than in the intensive insulin group (p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In patients with obesity, fatty liver and diabetes, the fatty liver reversal rate was significantly higher with exenatide (with background insulin glargine) than with intensive insulin aspart plus glargine.

    In plain wordsIn people with obesity, fatty liver and diabetes, fatty liver cleared more often with exenatide than with intensive insulin.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseFatty liver reversal
    Study

    n = 60

    Comparator
    Insulin aspart plus insulin glargine
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Reversal rate
    93.3%
    exenatide combination
    Reversal rate
    66.7%
    intensive insulin

    Source sentences

    Summary
    Moreover, the reversal rate of fatty liver was significantly higher in the exenatide group (93.3%) than the intensive insulin group (66.7%) (p < 0.01).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.

Studies that did not test the peptide alone9

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

  1. 07HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    Fasting glucose fell in both regimens, including exenatide plus glargine, in patients with obesity, fatty liver and diabetes.

    In plain wordsFasting glucose fell in both treatment groups, including the exenatide combination.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseFasting blood glucose
    Study

    n = 60

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After 12 weeks, fasting blood glucose (FBG), postprandial blood glucose (PBG), glycosylated haemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG) and total bilirubin levels were significantly decreased in the two groups (p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  2. 08HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    Postprandial glucose fell in both regimens in patients with obesity, fatty liver and diabetes.

    In plain wordsAfter-meal glucose fell in both treatment groups, including the exenatide combination.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreasePostprandial blood glucose
    Study

    n = 60

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After 12 weeks, fasting blood glucose (FBG), postprandial blood glucose (PBG), glycosylated haemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG) and total bilirubin levels were significantly decreased in the two groups (p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  3. 09HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    HbA1c fell in both regimens in patients with obesity, fatty liver and diabetes.

    In plain wordsHbA1c fell in both treatment groups, including the exenatide combination.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHbA1c
    Study

    n = 60

    Outcome group
    Glycemic control · Metabolic and weight

    Source sentences

    Summary
    After 12 weeks, fasting blood glucose (FBG), postprandial blood glucose (PBG), glycosylated haemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG) and total bilirubin levels were significantly decreased in the two groups (p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  4. 10HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    Total cholesterol fell in both regimens in patients with obesity, fatty liver and diabetes.

    In plain wordsTotal cholesterol fell in both treatment groups, including the exenatide combination.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTotal cholesterol
    Study

    n = 60

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    After 12 weeks, fasting blood glucose (FBG), postprandial blood glucose (PBG), glycosylated haemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG) and total bilirubin levels were significantly decreased in the two groups (p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  5. 11HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    Triglycerides fell in both regimens in patients with obesity, fatty liver and diabetes.

    In plain wordsTriglycerides fell in both treatment groups, including the exenatide combination.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTriglycerides
    Study

    n = 60

    Outcome group
    Lipids · Metabolic and weight

    Source sentences

    Summary
    After 12 weeks, fasting blood glucose (FBG), postprandial blood glucose (PBG), glycosylated haemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG) and total bilirubin levels were significantly decreased in the two groups (p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  6. 12HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialEfficacy outcome

    Total bilirubin fell in both regimens in patients with obesity, fatty liver and diabetes.

    In plain wordsBilirubin fell in both treatment groups, including the exenatide combination.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTotal bilirubin
    Study

    n = 60

    Outcome group
    Liver fat and liver function · Liver

    Source sentences

    Summary
    After 12 weeks, fasting blood glucose (FBG), postprandial blood glucose (PBG), glycosylated haemoglobin (HbA1c), total cholesterol (TC), triglyceride (TG) and total bilirubin levels were significantly decreased in the two groups (p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  7. 13HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther

    In the diabetes trial, weight change correlated with ALT change, without a stated arm-specific estimate.

    In plain wordsWeight change was linked to ALT change across an unspecified set of patients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableWeight change correlation with ALT
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver

    Measurements

    Correlation
    0.761 r
    weight and ALT changes

    Source sentences

    Summary
    The mean body weight change correlated with the levels of ALT, AST and γGGT change (ALT, r = 0.761; AST, r = 0.733; γGGT, r = 0.752; p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  8. 14HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther

    In the diabetes trial, weight change correlated with AST change, without a stated arm-specific estimate.

    In plain wordsWeight change was linked to AST change across an unspecified set of patients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableWeight change correlation with AST
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver

    Measurements

    Correlation
    0.733 r
    weight and AST changes

    Source sentences

    Summary
    The mean body weight change correlated with the levels of ALT, AST and γGGT change (ALT, r = 0.761; AST, r = 0.733; γGGT, r = 0.752; p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

  9. 15HumanNot a test of Exenatide (exendin-4) aloneRandomized controlled trialOther

    In the diabetes trial, weight change correlated with γGGT change, without a stated arm-specific estimate.

    In plain wordsWeight change was linked to γGGT change across an unspecified set of patients.

    Peptide
    Exenatide (exendin-4)
    Outcome
    Not applicableWeight change correlation with γGGT
    Study

    n: not reported in source

    Outcome group
    Liver fat and liver function · Liver

    Measurements

    Correlation
    0.752 r
    weight and γGGT changes

    Source sentences

    Summary
    The mean body weight change correlated with the levels of ALT, AST and γGGT change (ALT, r = 0.761; AST, r = 0.733; γGGT, r = 0.752; p < 0.001).
    2 context sentences
    Summary · context
    A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
    Summary · context
    The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.

    In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 4NCT02303730

Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes

Fudan Universityn = 76Mar 2015 to Nov 2017

Diabetes Mellitus, Type 2 · Non-alcoholic Fatty Liver Disease

Trial pageClinicalTrials.govUpdated 28 Aug 2019

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.